Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00609518
Registration number
NCT00609518
Ethics application status
Date submitted
23/01/2008
Date registered
7/02/2008
Date last updated
28/12/2010
Titles & IDs
Public title
A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer
Query!
Scientific title
Pemetrexed With Simplified Folate and Dexamethasone Supplementation Versus Pemetrexed With Standard Supplementation as Second-line Chemotherapy for Patients With Non-squamous Non-small Cell Lung Cancer
Query!
Secondary ID [1]
0
0
H3E-CR-S111
Query!
Secondary ID [2]
0
0
11652
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Non Small Cell Lung Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - pemetrexed
Other interventions - Folic acid
Other interventions - Folic Acid
Other interventions - Vitamin B12
Treatment: Drugs - dexamethasone
Treatment: Drugs - dexamethasone
Active Comparator: Standard Vitamin and Steroid Schedule + Pemetrexed - Standard vitamin and steroid schedule that is used with pemetrexed consisting of a minimum of 5 daily doses of folic acid before first pemetrexed dose and dexamethasone on day before, day of, and day after treatment.
Experimental: Simplified Vitamin and Steroid Schedule + Pemetrexed - Simplified vitamin and steroid schedule to be used with pemetrexed consisting of 2 daily doses of folic acid before first pemetrexed dose and dexamethasone on day of treatment only.
Treatment: Drugs: pemetrexed
500 mg/m^2 intravenous infusion on day 1 of each 21-day cycle. Number of Cycles: Until progression or to a maximum of 6 cycles.
Other interventions: Folic acid
350-1000 micrograms taken orally for at least 5 daily doses during the 7-day period prior to the first dose of pemetrexed then continues daily throughout treatment until 3 weeks after the last dose of pemetrexed.
Other interventions: Folic Acid
350-1000 micrograms taken orally for two consecutive daily doses of folic acid the day before and the day of the first dose of pemetrexed the continues throughout treatment and for 3 weeks after the last dose of pemetrexed.
Other interventions: Vitamin B12
1000 micrograms intramuscular injection of vitamin B12 during the week prior to the first dose of pemetrexed then further injections given approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.
Treatment: Drugs: dexamethasone
4 mg taken orally [or equivalent] twice per day the day before, the day of, and the day after the first day of pemetrexed. Continue to give dexamethasone twice per day the day before, the day of, and the day after each dose of pemetrexed.
Treatment: Drugs: dexamethasone
4 mg taken orally [or equivalent] twice per day on the day of the first dose of pemetrexed. Continue to give dexamethasone twice per day on the day of each dose of pemetrexed.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Safety: Number of Participants With Drug-Related Grade 3 or 4 Toxicity
Query!
Assessment method [1]
0
0
Results are presented for the number of participants with drug-related Grade 3 or 4 toxicity/adverse event (AE). Grades range from 0 (none) to 5 (death), with Grade 3 and 4 being defined as follows:
Grade 0 = No AE; Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE; Grade 5 = Death related to AE. A detailed list of Serious and non-serious adverse events is provided in the Reported Adverse Event section.
Query!
Timepoint [1]
0
0
From first dose of treatment to last dose of treatment plus 30 days
Query!
Secondary outcome [1]
0
0
Proportion of Participants With Best Overall Tumor Response (Response Rate)
Query!
Assessment method [1]
0
0
Response defined per Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. Best Overall Tumor Response is complete response plus partial response.
Query!
Timepoint [1]
0
0
Baseline until disease progression, new therapy initiated, or death from any cause, up to 12 months after enrollment.
Query!
Secondary outcome [2]
0
0
Overall Survival
Query!
Assessment method [2]
0
0
Overall survival is the duration from randomization to death. For patients who are alive, overall survival is censored at the date of last contact.
Query!
Timepoint [2]
0
0
Randomization (=4 weeks from baseline visit) to 12 months after randomization
Query!
Secondary outcome [3]
0
0
Progression-free Survival (PFS)
Query!
Assessment method [3]
0
0
Defined as the time from date of first dose to the first observation of disease progression, or death due to any cause. For patients who are alive and have not progressed, PFS is censored at the date of last radiological assessment.
Query!
Timepoint [3]
0
0
Randomization (=4 weeks from baseline visit) to 12 months after randomization
Query!
Eligibility
Key inclusion criteria
- Histologic or cytologic diagnosis of non-small cell lung cancer (NSCLC) with locally
advanced or metastatic disease (Stage IIIA, IIIB or IV)that is of non-squamous
histology
- Patients must have failed only one prior chemotherapy regime and must be considered
eligible for further chemotherapy following progression of their disease.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
- Adequate organ function
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Concurrent administration of any other anti-tumor therapy
- Other co-existing malignancies
- Pregnancy or breast feeding
- Serious concomitant disorders
- Inability or unwillingness to take folic acid or vitamin B12 supplementation
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/02/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/06/2010
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
111
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Query!
Recruitment hospital [1]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Bankstown
Query!
Recruitment hospital [2]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Concord
Query!
Recruitment hospital [3]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Kingswood Penrith
Query!
Recruitment hospital [4]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Liverpool
Query!
Recruitment hospital [5]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Redcliffe
Query!
Recruitment postcode(s) [1]
0
0
2200 - Bankstown
Query!
Recruitment postcode(s) [2]
0
0
2139 - Concord
Query!
Recruitment postcode(s) [3]
0
0
2747 - Kingswood Penrith
Query!
Recruitment postcode(s) [4]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [5]
0
0
4020 - Redcliffe
Query!
Recruitment outside Australia
Country [1]
0
0
Italy
Query!
State/province [1]
0
0
Bologna
Query!
Country [2]
0
0
Italy
Query!
State/province [2]
0
0
Milano
Query!
Country [3]
0
0
Italy
Query!
State/province [3]
0
0
Napoli
Query!
Country [4]
0
0
Italy
Query!
State/province [4]
0
0
Pisa
Query!
Country [5]
0
0
Italy
Query!
State/province [5]
0
0
Rome
Query!
Country [6]
0
0
Mexico
Query!
State/province [6]
0
0
Mexico City
Query!
Country [7]
0
0
Mexico
Query!
State/province [7]
0
0
Toluca
Query!
Country [8]
0
0
Spain
Query!
State/province [8]
0
0
Pozuelo De Alarcon
Query!
Country [9]
0
0
Spain
Query!
State/province [9]
0
0
Sevilla
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Chemotherapy for patients with non-squamous non-small cell lung cancer. Patients are given
folic acid, vitamin B12 and steroids, both before and during treatment, to reduce the side
effects associated with pemetrexed. The aim is whether it is possible to simplify the folic
acid and steroid schedule without increasing toxicity.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00609518
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Query!
Address
0
0
Eli Lilly and Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00609518
Download to PDF